Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.22
- Piotroski Score 1.00
- Grade N/A
- Symbol (ADEX)
- Company Adit EdTech Acquisition Corp.
- Price $5.38
- Changes Percentage (4.47%)
- Change $0.23
- Day Low $4.93
- Day High $6.50
- Year High $12.39
Adit EdTech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/30/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.19
- Trailing P/E Ratio -28.315789473684
- Forward P/E Ratio -28.315789473684
- P/E Growth -28.315789473684
- Net Income $-18,657,000
Income Statement
Quarterly
Annual
Latest News of ADEX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
CEO Robert Fried clarified that the $6.4 million improvement in net income was due to changes in working capital. Niagen IV doses are priced at $500-$700 and categorized as pharmaceutical grade sales....
By Yahoo! Finance | 3 weeks ago -
When Will ChromaDex Corporation (NASDAQ:CDXC) Turn A Profit?
ChromaDex Corporation is a bioscience company focusing on healthy aging products, with reduced losses as it approaches breakeven. Analysts predict profitability by 2025, expecting 99% annual growth. T...
By Yahoo! Finance | 4 months ago -
Here's Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Looks Fair
ChromaDex's shareholders have faced a 67% loss in the past three years, but the EPS has grown by 54%. CEO Rob Fried's compensation seems reasonable, with a salary below the industry median....
By Yahoo! Finance | 5 months ago
